Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyPTC299
Identification
- Name
- PTC299
- Accession Number
- DB05173
- Type
- Small Molecule
- Groups
- Investigational
- Description
PTC299 is a novel, orally administered small-molecule designed to inhibit the production of vascular endothelial growth factor (VEGF) in tumors. Overexpression of VEGF plays a key role in multiple diseases including cancer and macular degeneration. PTC299 was discovered through PTC's GEMS technology by targeting the post-transcriptional processes that regulate VEGF formation, and is currently being developed for the treatment of cancer.
- Synonyms
- Not Available
- Categories
- UNII
- Not Available
- CAS number
- Not Available
- Weight
- Not Available
- Chemical Formula
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
Pharmacology
- Indication
Investigated for use/treatment in cancer/tumors (unspecified) and solid tumors.
- Pharmacodynamics
PTC299 demonstrated a broad range of activity in blocking VEGF synthesis in multiple tumor types, including breast, cervical, colorectal, fibrosarcoma, gastric, lung, melanoma, neuroblastoma, ovarian, pancreatic, prostate and renal cell cancer lines. PTC299 as a monotherapy significantly reduced VEGF concentrations in tumors and plasma, reduced tumor blood vessel density, and substantially impeded tumor progression.
- Mechanism of action
PTC299 was designed to inhibit VEGF production in tumors by targeting the post-transcriptional control processes that regulate VEGF formation. Because PTC299 inhibits VEGF production, its action occurs at a different point in the VEGF pathway than therapies, such as Avastin® or Sutent®. PTC299 may be active both as a single agent or when used in combination with other anti-angiogenic agents or with chemotherapy agents for the treatment of cancers.
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
- Not Available
- Affected organisms
- Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group (4R)-limonene The risk or severity of adverse effects can be increased when PTC299 is combined with (4R)-limonene. Investigational 16-Bromoepiandrosterone The risk or severity of adverse effects can be increased when PTC299 is combined with 16-Bromoepiandrosterone. Investigational 19-norandrostenedione The risk or severity of adverse effects can be increased when PTC299 is combined with 19-norandrostenedione. Experimental, Illicit 5-androstenedione The risk or severity of adverse effects can be increased when PTC299 is combined with 5-androstenedione. Experimental, Illicit Acebutolol PTC299 may decrease the antihypertensive activities of Acebutolol. Approved, Investigational Aceclofenac The risk or severity of adverse effects can be increased when PTC299 is combined with Aceclofenac. Approved, Investigational Acemetacin The risk or severity of adverse effects can be increased when PTC299 is combined with Acemetacin. Approved, Experimental, Investigational Acenocoumarol PTC299 may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Acetylsalicylic acid. Approved, Vet Approved Adapalene The risk or severity of adverse effects can be increased when Adapalene is combined with PTC299. Approved Alclofenac The risk or severity of adverse effects can be increased when PTC299 is combined with Alclofenac. Approved, Withdrawn Alclometasone The risk or severity of adverse effects can be increased when PTC299 is combined with Alclometasone. Approved Aldosterone The risk or severity of adverse effects can be increased when PTC299 is combined with Aldosterone. Experimental, Investigational Alendronic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Alendronic acid. Approved Aliskiren PTC299 may decrease the antihypertensive activities of Aliskiren. Approved, Investigational Alminoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Alminoprofen. Experimental Alprenolol PTC299 may decrease the antihypertensive activities of Alprenolol. Approved, Withdrawn Alprostadil The therapeutic efficacy of Alprostadil can be decreased when used in combination with PTC299. Approved, Investigational Amcinonide The risk or severity of adverse effects can be increased when PTC299 is combined with Amcinonide. Approved Amiloride PTC299 may decrease the antihypertensive activities of Amiloride. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when PTC299 is combined with Aminosalicylic Acid. Approved Ancrod PTC299 may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide The risk or severity of adverse effects can be increased when PTC299 is combined with Andrographolide. Investigational Androstenedione The risk or severity of adverse effects can be increased when PTC299 is combined with Androstenedione. Experimental, Illicit Anecortave The risk or severity of adverse effects can be increased when PTC299 is combined with Anecortave. Investigational anecortave acetate The risk or severity of adverse effects can be increased when PTC299 is combined with anecortave acetate. Investigational Anisodamine The risk or severity of adverse effects can be increased when PTC299 is combined with Anisodamine. Investigational Antipyrine The risk or severity of adverse effects can be increased when PTC299 is combined with Antipyrine. Approved, Investigational Antithrombin III human PTC299 may increase the anticoagulant activities of Antithrombin III human. Approved Antrafenine The risk or severity of adverse effects can be increased when PTC299 is combined with Antrafenine. Approved Apixaban PTC299 may increase the anticoagulant activities of Apixaban. Approved Apocynin The risk or severity of adverse effects can be increased when PTC299 is combined with Apocynin. Investigational Apramycin PTC299 may decrease the excretion rate of Apramycin which could result in a higher serum level. Experimental, Vet Approved Apremilast The risk or severity of adverse effects can be increased when PTC299 is combined with Apremilast. Approved, Investigational Arbekacin PTC299 may decrease the excretion rate of Arbekacin which could result in a higher serum level. Approved, Investigational Ardeparin PTC299 may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban PTC299 may increase the anticoagulant activities of Argatroban. Approved, Investigational Arotinolol PTC299 may decrease the antihypertensive activities of Arotinolol. Investigational Asenapine PTC299 may decrease the antihypertensive activities of Asenapine. Approved Atamestane The risk or severity of adverse effects can be increased when PTC299 is combined with Atamestane. Investigational Atenolol PTC299 may decrease the antihypertensive activities of Atenolol. Approved Azapropazone The risk or severity of adverse effects can be increased when PTC299 is combined with Azapropazone. Withdrawn Azelastine The risk or severity of adverse effects can be increased when Azelastine is combined with PTC299. Approved Azficel-T The risk or severity of adverse effects can be increased when PTC299 is combined with Azficel-T. Approved, Investigational Azilsartan medoxomil The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with PTC299. Approved, Investigational Azosemide The therapeutic efficacy of Azosemide can be decreased when used in combination with PTC299. Investigational Balsalazide The risk or severity of adverse effects can be increased when PTC299 is combined with Balsalazide. Approved, Investigational Becaplermin PTC299 may increase the anticoagulant activities of Becaplermin. Approved, Investigational Befunolol PTC299 may decrease the antihypertensive activities of Befunolol. Experimental Bekanamycin PTC299 may decrease the excretion rate of Bekanamycin which could result in a higher serum level. Experimental Benazepril The risk or severity of adverse effects can be increased when PTC299 is combined with Benazepril. Approved, Investigational Bendazac The risk or severity of adverse effects can be increased when PTC299 is combined with Bendazac. Experimental Bendroflumethiazide The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with PTC299. Approved Benorilate The risk or severity of adverse effects can be increased when PTC299 is combined with Benorilate. Experimental Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with PTC299. Withdrawn Benzthiazide The therapeutic efficacy of Benzthiazide can be decreased when used in combination with PTC299. Approved Benzydamine The risk or severity of adverse effects can be increased when PTC299 is combined with Benzydamine. Approved Beraprost The therapeutic efficacy of Beraprost can be decreased when used in combination with PTC299. Investigational Betamethasone The risk or severity of adverse effects can be increased when PTC299 is combined with Betamethasone. Approved, Vet Approved Betaxolol PTC299 may decrease the antihypertensive activities of Betaxolol. Approved, Investigational Betrixaban The risk or severity of bleeding can be increased when Betrixaban is combined with PTC299. Approved, Investigational Bevantolol PTC299 may decrease the antihypertensive activities of Bevantolol. Approved Bevonium The risk or severity of adverse effects can be increased when PTC299 is combined with Bevonium. Experimental Bimatoprost The therapeutic efficacy of Bimatoprost can be decreased when used in combination with PTC299. Approved, Investigational Bisoprolol PTC299 may decrease the antihypertensive activities of Bisoprolol. Approved Bopindolol PTC299 may decrease the antihypertensive activities of Bopindolol. Approved Bromfenac The risk or severity of adverse effects can be increased when PTC299 is combined with Bromfenac. Approved Bucillamine The risk or severity of adverse effects can be increased when PTC299 is combined with Bucillamine. Investigational Bucindolol PTC299 may decrease the antihypertensive activities of Bucindolol. Investigational Bufexamac The risk or severity of adverse effects can be increased when PTC299 is combined with Bufexamac. Approved, Experimental Bufuralol PTC299 may decrease the antihypertensive activities of Bufuralol. Experimental, Investigational Bumadizone The risk or severity of adverse effects can be increased when PTC299 is combined with Bumadizone. Experimental Bumetanide The therapeutic efficacy of Bumetanide can be decreased when used in combination with PTC299. Approved Bupranolol PTC299 may decrease the antihypertensive activities of Bupranolol. Approved Candesartan The risk or severity of adverse effects can be increased when Candesartan is combined with PTC299. Experimental Candesartan cilexetil The risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with PTC299. Approved Candoxatril The risk or severity of adverse effects can be increased when PTC299 is combined with Candoxatril. Experimental Capsaicin The risk or severity of adverse effects can be increased when PTC299 is combined with Capsaicin. Approved Captopril The risk or severity of adverse effects can be increased when PTC299 is combined with Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when PTC299 is combined with Carbaspirin calcium. Experimental, Investigational Carboprost Tromethamine The therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with PTC299. Approved Carprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Carprofen. Approved, Vet Approved, Withdrawn Carteolol PTC299 may decrease the antihypertensive activities of Carteolol. Approved Castanospermine The risk or severity of adverse effects can be increased when Castanospermine is combined with PTC299. Experimental Celecoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Celecoxib. Approved, Investigational Celiprolol PTC299 may decrease the antihypertensive activities of Celiprolol. Approved, Investigational Certoparin PTC299 may increase the anticoagulant activities of Certoparin. Approved, Investigational Chloroquine The risk or severity of adverse effects can be increased when Chloroquine is combined with PTC299. Approved, Investigational, Vet Approved Chlorothiazide The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with PTC299. Approved, Vet Approved Chlorphenesin The risk or severity of adverse effects can be increased when PTC299 is combined with Chlorphenesin. Approved, Vet Approved, Withdrawn Chlorthalidone The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with PTC299. Approved Cholestyramine Cholestyramine can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved, Investigational Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when PTC299 is combined with Choline magnesium trisalicylate. Approved Ciclesonide The risk or severity of adverse effects can be increased when PTC299 is combined with Ciclesonide. Approved, Investigational Cilazapril The risk or severity of adverse effects can be increased when PTC299 is combined with Cilazapril. Approved Cimicoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Cimicoxib. Investigational Cinoxacin PTC299 may increase the neuroexcitatory activities of Cinoxacin. Approved, Investigational, Withdrawn Cisplatin The risk or severity of adverse effects can be increased when PTC299 is combined with Cisplatin. Approved Clobetasol The risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasol. Approved, Investigational Clobetasol propionate The risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasol propionate. Approved Clobetasone The risk or severity of adverse effects can be increased when PTC299 is combined with Clobetasone. Approved Clocortolone The risk or severity of adverse effects can be increased when PTC299 is combined with Clocortolone. Approved Clodronic Acid The risk or severity of adverse effects can be increased when PTC299 is combined with Clodronic Acid. Approved, Investigational, Vet Approved Clonixin The risk or severity of adverse effects can be increased when PTC299 is combined with Clonixin. Approved Cloprostenol The therapeutic efficacy of Cloprostenol can be decreased when used in combination with PTC299. Vet Approved Cloranolol PTC299 may decrease the antihypertensive activities of Cloranolol. Experimental Colesevelam Colesevelam can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Colestipol Colestipol can cause a decrease in the absorption of PTC299 resulting in a reduced serum concentration and potentially a decrease in efficacy. Approved Cortexolone 17α-propionate The risk or severity of adverse effects can be increased when PTC299 is combined with Cortexolone 17α-propionate. Investigational Corticosterone The risk or severity of adverse effects can be increased when PTC299 is combined with Corticosterone. Experimental Cortisone acetate The risk or severity of adverse effects can be increased when PTC299 is combined with Cortisone acetate. Approved, Investigational Curcumin The risk or severity of adverse effects can be increased when PTC299 is combined with Curcumin. Approved, Investigational Cyclopenthiazide The therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with PTC299. Experimental Dabigatran etexilate PTC299 may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin PTC299 may increase the anticoagulant activities of Dalteparin. Approved Danaparoid PTC299 may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban PTC299 may increase the anticoagulant activities of Darexaban. Investigational Deferasirox The risk or severity of adverse effects can be increased when PTC299 is combined with Deferasirox. Approved, Investigational Deflazacort The risk or severity of adverse effects can be increased when PTC299 is combined with Deflazacort. Approved, Investigational Delapril The risk or severity of adverse effects can be increased when PTC299 is combined with Delapril. Investigational Desipramine PTC299 may decrease the antihypertensive activities of Desipramine. Approved, Investigational Desirudin PTC299 may increase the anticoagulant activities of Desirudin. Approved Desonide The risk or severity of adverse effects can be increased when PTC299 is combined with Desonide. Approved, Investigational Desoximetasone The risk or severity of adverse effects can be increased when PTC299 is combined with Desoximetasone. Approved Desoxycorticosterone acetate The risk or severity of adverse effects can be increased when PTC299 is combined with Desoxycorticosterone acetate. Approved Desoxycorticosterone Pivalate The risk or severity of adverse effects can be increased when PTC299 is combined with Desoxycorticosterone Pivalate. Experimental, Vet Approved Dexamethasone isonicotinate The risk or severity of adverse effects can be increased when PTC299 is combined with Dexamethasone isonicotinate. Vet Approved Dexibuprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Dexibuprofen. Approved, Investigational Dexketoprofen The risk or severity of adverse effects can be increased when Dexketoprofen is combined with PTC299. Approved, Investigational Dextran PTC299 may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Dibekacin PTC299 may decrease the excretion rate of Dibekacin which could result in a higher serum level. Experimental Dibotermin alfa The risk or severity of adverse effects can be increased when PTC299 is combined with Dibotermin alfa. Approved, Investigational Dicoumarol PTC299 may increase the anticoagulant activities of Dicoumarol. Approved Difenpiramide The risk or severity of adverse effects can be increased when PTC299 is combined with Difenpiramide. Experimental Diflorasone The risk or severity of adverse effects can be increased when PTC299 is combined with Diflorasone. Approved Diflunisal The risk or severity of adverse effects can be increased when PTC299 is combined with Diflunisal. Approved, Investigational Difluocortolone The risk or severity of adverse effects can be increased when PTC299 is combined with Difluocortolone. Approved, Investigational, Withdrawn Difluprednate The risk or severity of adverse effects can be increased when PTC299 is combined with Difluprednate. Approved Digoxin The serum concentration of Digoxin can be increased when it is combined with PTC299. Approved Dihydrostreptomycin PTC299 may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level. Investigational, Vet Approved Dinoprost The therapeutic efficacy of Dinoprost can be decreased when used in combination with PTC299. Investigational Dinoprost Tromethamine The therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with PTC299. Approved, Vet Approved Dinoprostone The therapeutic efficacy of Dinoprostone can be decreased when used in combination with PTC299. Approved Drospirenone PTC299 may increase the hyperkalemic activities of Drospirenone. Approved Droxicam The risk or severity of adverse effects can be increased when PTC299 is combined with Droxicam. Withdrawn Duvelisib The risk or severity of adverse effects can be increased when PTC299 is combined with Duvelisib. Investigational E-6201 The risk or severity of adverse effects can be increased when PTC299 is combined with E-6201. Investigational Edetic Acid PTC299 may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban PTC299 may increase the anticoagulant activities of Edoxaban. Approved Enalapril The risk or severity of adverse effects can be increased when PTC299 is combined with Enalapril. Approved, Vet Approved Enalaprilat The risk or severity of adverse effects can be increased when PTC299 is combined with Enalaprilat. Approved Enoxacin PTC299 may increase the neuroexcitatory activities of Enoxacin. Approved, Investigational Enoxaparin PTC299 may increase the anticoagulant activities of Enoxaparin. Approved Enprostil The therapeutic efficacy of Enprostil can be decreased when used in combination with PTC299. Experimental Epanolol PTC299 may decrease the antihypertensive activities of Epanolol. Experimental Epirizole The risk or severity of adverse effects can be increased when PTC299 is combined with Epirizole. Approved Epitizide The therapeutic efficacy of Epitizide can be decreased when used in combination with PTC299. Experimental Eplerenone PTC299 may decrease the antihypertensive activities of Eplerenone. Approved Epoprostenol The therapeutic efficacy of Epoprostenol can be decreased when used in combination with PTC299. Approved Eprosartan The risk or severity of adverse effects can be increased when Eprosartan is combined with PTC299. Approved Equilenin The risk or severity of adverse effects can be increased when PTC299 is combined with Equilenin. Experimental Equilin The risk or severity of adverse effects can be increased when PTC299 is combined with Equilin. Approved Esatenolol PTC299 may decrease the antihypertensive activities of Esatenolol. Experimental Esmolol PTC299 may decrease the antihypertensive activities of Esmolol. Approved Estrone The risk or severity of adverse effects can be increased when PTC299 is combined with Estrone. Approved Estrone sulfate The risk or severity of adverse effects can be increased when PTC299 is combined with Estrone sulfate. Approved Etacrynic acid The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with PTC299. Approved, Investigational Ethenzamide The risk or severity of adverse effects can be increased when PTC299 is combined with Ethenzamide. Experimental Ethyl biscoumacetate PTC299 may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etidronic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Etidronic acid. Approved Etodolac The risk or severity of adverse effects can be increased when PTC299 is combined with Etodolac. Approved, Investigational, Vet Approved Etofenamate The risk or severity of adverse effects can be increased when PTC299 is combined with Etofenamate. Approved, Investigational Etoricoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Etoricoxib. Approved, Investigational Evening primrose oil The risk or severity of adverse effects can be increased when PTC299 is combined with Evening primrose oil. Investigational, Nutraceutical Exisulind The risk or severity of adverse effects can be increased when PTC299 is combined with Exisulind. Investigational Felbinac The risk or severity of adverse effects can be increased when PTC299 is combined with Felbinac. Experimental Fenbufen The risk or severity of adverse effects can be increased when PTC299 is combined with Fenbufen. Approved Fenoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Fenoprofen. Approved Fenprostalene The therapeutic efficacy of Fenprostalene can be decreased when used in combination with PTC299. Vet Approved Fentiazac The risk or severity of adverse effects can be increased when PTC299 is combined with Fentiazac. Experimental Feprazone The risk or severity of adverse effects can be increased when PTC299 is combined with Feprazone. Experimental Ferulic acid PTC299 may increase the anticoagulant activities of Ferulic acid. Experimental Fimasartan The risk or severity of adverse effects can be increased when Fimasartan is combined with PTC299. Approved, Investigational Fleroxacin PTC299 may increase the neuroexcitatory activities of Fleroxacin. Approved Floctafenine The risk or severity of adverse effects can be increased when Floctafenine is combined with PTC299. Approved, Withdrawn Fluasterone The risk or severity of adverse effects can be increased when PTC299 is combined with Fluasterone. Investigational Fludrocortisone The risk or severity of adverse effects can be increased when PTC299 is combined with Fludrocortisone. Approved, Investigational Fluindione PTC299 may increase the anticoagulant activities of Fluindione. Approved, Investigational Flumequine PTC299 may increase the neuroexcitatory activities of Flumequine. Withdrawn Flumethasone The risk or severity of adverse effects can be increased when PTC299 is combined with Flumethasone. Approved, Vet Approved Flunisolide The risk or severity of adverse effects can be increased when PTC299 is combined with Flunisolide. Approved, Investigational Flunixin The risk or severity of adverse effects can be increased when PTC299 is combined with Flunixin. Vet Approved Flunoxaprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Flunoxaprofen. Experimental Fluocinolone Acetonide The risk or severity of adverse effects can be increased when PTC299 is combined with Fluocinolone Acetonide. Approved, Investigational, Vet Approved Fluocinonide The risk or severity of adverse effects can be increased when PTC299 is combined with Fluocinonide. Approved, Investigational Fluocortolone The risk or severity of adverse effects can be increased when PTC299 is combined with Fluocortolone. Approved, Withdrawn Fluorometholone The risk or severity of adverse effects can be increased when PTC299 is combined with Fluorometholone. Approved, Investigational Fluprednidene The risk or severity of adverse effects can be increased when PTC299 is combined with Fluprednidene. Approved, Withdrawn Fluprednisolone The risk or severity of adverse effects can be increased when PTC299 is combined with Fluprednisolone. Approved Fluprostenol The therapeutic efficacy of Fluprostenol can be decreased when used in combination with PTC299. Vet Approved Flurandrenolide The risk or severity of adverse effects can be increased when PTC299 is combined with Flurandrenolide. Approved Flurbiprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Flurbiprofen. Approved, Investigational Fluticasone The risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone. Approved, Experimental, Investigational Fluticasone furoate The risk or severity of adverse effects can be increased when PTC299 is combined with Fluticasone furoate. Approved Folic Acid The therapeutic efficacy of Folic Acid can be decreased when used in combination with PTC299. Approved, Nutraceutical, Vet Approved Fondaparinux PTC299 may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Forasartan The risk or severity of adverse effects can be increased when Forasartan is combined with PTC299. Experimental Formestane The risk or severity of adverse effects can be increased when PTC299 is combined with Formestane. Approved, Investigational, Withdrawn Framycetin PTC299 may decrease the excretion rate of Framycetin which could result in a higher serum level. Approved Gabexate PTC299 may increase the anticoagulant activities of Gabexate. Investigational Garenoxacin PTC299 may increase the neuroexcitatory activities of Garenoxacin. Investigational Gatifloxacin PTC299 may increase the neuroexcitatory activities of Gatifloxacin. Approved, Investigational Gemeprost The therapeutic efficacy of Gemeprost can be decreased when used in combination with PTC299. Approved, Withdrawn Gemifloxacin PTC299 may increase the neuroexcitatory activities of Gemifloxacin. Approved, Investigational Geneticin PTC299 may decrease the excretion rate of Geneticin which could result in a higher serum level. Experimental Gentamicin PTC299 may decrease the excretion rate of Gentamicin which could result in a higher serum level. Approved, Vet Approved GENTAMICIN C1A PTC299 may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level. Experimental Ginseng The risk or severity of adverse effects can be increased when PTC299 is combined with Ginseng. Approved, Investigational, Nutraceutical Grepafloxacin PTC299 may increase the neuroexcitatory activities of Grepafloxacin. Approved, Investigational, Withdrawn Guacetisal The risk or severity of adverse effects can be increased when PTC299 is combined with Guacetisal. Experimental Halcinonide The risk or severity of adverse effects can be increased when PTC299 is combined with Halcinonide. Approved, Investigational, Withdrawn Haloperidol The risk or severity of adverse effects can be increased when PTC299 is combined with Haloperidol. Approved HE3286 The risk or severity of adverse effects can be increased when PTC299 is combined with HE3286. Investigational Heparin PTC299 may increase the anticoagulant activities of Heparin. Approved, Investigational Higenamine The risk or severity of adverse effects can be increased when PTC299 is combined with Higenamine. Investigational Hydralazine PTC299 may decrease the antihypertensive activities of Hydralazine. Approved Hydroflumethiazide The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with PTC299. Approved, Investigational Hygromycin B PTC299 may decrease the excretion rate of Hygromycin B which could result in a higher serum level. Vet Approved Ibuproxam The risk or severity of adverse effects can be increased when PTC299 is combined with Ibuproxam. Withdrawn Icatibant The risk or severity of adverse effects can be increased when PTC299 is combined with Icatibant. Approved, Investigational Icosapent The risk or severity of adverse effects can be increased when PTC299 is combined with Icosapent. Approved, Nutraceutical Idraparinux PTC299 may increase the anticoagulant activities of Idraparinux. Investigational Iloprost The therapeutic efficacy of Iloprost can be decreased when used in combination with PTC299. Approved, Investigational Imidapril The risk or severity of adverse effects can be increased when PTC299 is combined with Imidapril. Investigational Imidazole salicylate The risk or severity of adverse effects can be increased when PTC299 is combined with Imidazole salicylate. Experimental Indapamide The therapeutic efficacy of Indapamide can be decreased when used in combination with PTC299. Approved Indenolol PTC299 may decrease the antihypertensive activities of Indenolol. Withdrawn Indobufen The risk or severity of adverse effects can be increased when PTC299 is combined with Indobufen. Investigational Indomethacin The risk or severity of adverse effects can be increased when PTC299 is combined with Indomethacin. Approved, Investigational Indoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Indoprofen. Withdrawn Irbesartan The risk or severity of adverse effects can be increased when Irbesartan is combined with PTC299. Approved, Investigational Isepamicin PTC299 may decrease the excretion rate of Isepamicin which could result in a higher serum level. Experimental Isoxicam The risk or severity of adverse effects can be increased when PTC299 is combined with Isoxicam. Withdrawn Istaroxime The risk or severity of adverse effects can be increased when PTC299 is combined with Istaroxime. Investigational Kanamycin PTC299 may decrease the excretion rate of Kanamycin which could result in a higher serum level. Approved, Investigational, Vet Approved Kebuzone The risk or severity of adverse effects can be increased when PTC299 is combined with Kebuzone. Experimental Ketoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Ketoprofen. Approved, Vet Approved Landiolol PTC299 may decrease the antihypertensive activities of Landiolol. Investigational Latanoprostene Bunod The therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with PTC299. Approved, Investigational Leflunomide The risk or severity of adverse effects can be increased when Leflunomide is combined with PTC299. Approved, Investigational Lepirudin PTC299 may increase the anticoagulant activities of Lepirudin. Approved Letaxaban PTC299 may increase the anticoagulant activities of Letaxaban. Investigational Levobetaxolol PTC299 may decrease the antihypertensive activities of Levobetaxolol. Approved, Investigational Levobunolol PTC299 may decrease the antihypertensive activities of Levobunolol. Approved Levofloxacin PTC299 may increase the neuroexcitatory activities of Levofloxacin. Approved, Investigational Limaprost The therapeutic efficacy of Limaprost can be decreased when used in combination with PTC299. Approved, Investigational Lisinopril The risk or severity of adverse effects can be increased when PTC299 is combined with Lisinopril. Approved, Investigational Lisofylline The risk or severity of adverse effects can be increased when PTC299 is combined with Lisofylline. Investigational Lithium cation The serum concentration of Lithium can be increased when it is combined with PTC299. Experimental Lomefloxacin PTC299 may increase the neuroexcitatory activities of Lomefloxacin. Approved, Investigational Lonazolac The risk or severity of adverse effects can be increased when PTC299 is combined with Lonazolac. Experimental Lornoxicam The risk or severity of adverse effects can be increased when PTC299 is combined with Lornoxicam. Approved, Investigational Loteprednol The risk or severity of adverse effects can be increased when PTC299 is combined with Loteprednol. Approved Loxoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Loxoprofen. Approved, Investigational Lubiprostone The therapeutic efficacy of Lubiprostone can be decreased when used in combination with PTC299. Approved, Investigational Lumiracoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Lumiracoxib. Approved, Investigational Luprostiol The therapeutic efficacy of Luprostiol can be decreased when used in combination with PTC299. Vet Approved Magnesium salicylate The risk or severity of adverse effects can be increased when PTC299 is combined with Magnesium salicylate. Approved Masoprocol The risk or severity of adverse effects can be increased when Masoprocol is combined with PTC299. Approved, Investigational ME-609 The risk or severity of adverse effects can be increased when PTC299 is combined with ME-609. Investigational Meclofenamic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Meclofenamic acid. Approved, Vet Approved Medrysone The risk or severity of adverse effects can be increased when PTC299 is combined with Medrysone. Approved Mefenamic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Mefenamic acid. Approved Melagatran PTC299 may increase the anticoagulant activities of Melagatran. Experimental Melengestrol The risk or severity of adverse effects can be increased when PTC299 is combined with Melengestrol. Vet Approved Meloxicam The risk or severity of adverse effects can be increased when PTC299 is combined with Meloxicam. Approved, Vet Approved Mepindolol PTC299 may decrease the antihypertensive activities of Mepindolol. Experimental Mesalazine The risk or severity of adverse effects can be increased when PTC299 is combined with Mesalazine. Approved Metamizole The risk or severity of adverse effects can be increased when Metamizole is combined with PTC299. Approved, Investigational, Withdrawn Methotrexate The serum concentration of Methotrexate can be increased when it is combined with PTC299. Approved Methyclothiazide The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with PTC299. Approved Metipranolol PTC299 may decrease the antihypertensive activities of Metipranolol. Approved Metolazone The therapeutic efficacy of Metolazone can be decreased when used in combination with PTC299. Approved Micronomicin PTC299 may decrease the excretion rate of Micronomicin which could result in a higher serum level. Experimental Mifamurtide The therapeutic efficacy of Mifamurtide can be decreased when used in combination with PTC299. Approved, Experimental Misoprostol The therapeutic efficacy of Misoprostol can be decreased when used in combination with PTC299. Approved Mizoribine The risk or severity of adverse effects can be increased when PTC299 is combined with Mizoribine. Investigational Moexipril The risk or severity of adverse effects can be increased when PTC299 is combined with Moexipril. Approved Mofebutazone The risk or severity of adverse effects can be increased when PTC299 is combined with Mofebutazone. Experimental Mometasone The risk or severity of adverse effects can be increased when PTC299 is combined with Mometasone. Approved, Vet Approved Morniflumate The risk or severity of adverse effects can be increased when Morniflumate is combined with PTC299. Approved Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with PTC299. Approved, Investigational Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with PTC299. Approved Nabumetone The risk or severity of adverse effects can be increased when PTC299 is combined with Nabumetone. Approved Nadolol PTC299 may decrease the antihypertensive activities of Nadolol. Approved Nadroparin PTC299 may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat PTC299 may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftifine The risk or severity of adverse effects can be increased when Naftifine is combined with PTC299. Approved Nalidixic Acid PTC299 may increase the neuroexcitatory activities of Nalidixic Acid. Approved, Investigational NCX 1022 The risk or severity of adverse effects can be increased when PTC299 is combined with NCX 1022. Investigational Neamine PTC299 may decrease the excretion rate of Neamine which could result in a higher serum level. Experimental Nebivolol PTC299 may decrease the antihypertensive activities of Nebivolol. Approved, Investigational Nemonoxacin PTC299 may increase the neuroexcitatory activities of Nemonoxacin. Investigational Nepafenac The risk or severity of adverse effects can be increased when PTC299 is combined with Nepafenac. Approved, Investigational Netilmicin PTC299 may decrease the excretion rate of Netilmicin which could result in a higher serum level. Approved, Investigational Nifenazone The risk or severity of adverse effects can be increased when PTC299 is combined with Nifenazone. Experimental Niflumic Acid The risk or severity of adverse effects can be increased when PTC299 is combined with Niflumic Acid. Approved Nitroaspirin The risk or severity of adverse effects can be increased when PTC299 is combined with Nitroaspirin. Investigational Norfloxacin PTC299 may increase the neuroexcitatory activities of Norfloxacin. Approved Ofloxacin PTC299 may increase the neuroexcitatory activities of Ofloxacin. Approved Oleoyl-estrone The risk or severity of adverse effects can be increased when PTC299 is combined with Oleoyl-estrone. Investigational Olmesartan The risk or severity of adverse effects can be increased when Olmesartan is combined with PTC299. Approved, Investigational Olopatadine The risk or severity of adverse effects can be increased when Olopatadine is combined with PTC299. Approved Olsalazine PTC299 may increase the nephrotoxic activities of Olsalazine. Approved Omacetaxine mepesuccinate The risk or severity of bleeding can be increased when PTC299 is combined with Omacetaxine mepesuccinate. Approved, Investigational Omapatrilat The risk or severity of adverse effects can be increased when PTC299 is combined with Omapatrilat. Investigational Orgotein The risk or severity of adverse effects can be increased when PTC299 is combined with Orgotein. Vet Approved Otamixaban PTC299 may increase the anticoagulant activities of Otamixaban. Investigational Oxaprozin The risk or severity of adverse effects can be increased when PTC299 is combined with Oxaprozin. Approved Oxolinic acid PTC299 may increase the neuroexcitatory activities of Oxolinic acid. Experimental Oxprenolol PTC299 may decrease the antihypertensive activities of Oxprenolol. Approved Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with PTC299. Approved, Withdrawn Palmidrol The risk or severity of adverse effects can be increased when PTC299 is combined with Palmidrol. Experimental, Nutraceutical Pamidronate The risk or severity of adverse effects can be increased when PTC299 is combined with Pamidronate. Approved Paramethasone The risk or severity of adverse effects can be increased when PTC299 is combined with Paramethasone. Approved Parecoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Parecoxib. Approved Parthenolide The risk or severity of adverse effects can be increased when PTC299 is combined with Parthenolide. Approved, Investigational Pazufloxacin PTC299 may increase the neuroexcitatory activities of Pazufloxacin. Investigational Pefloxacin PTC299 may increase the neuroexcitatory activities of Pefloxacin. Approved Penbutolol PTC299 may decrease the antihypertensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate PTC299 may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentosan Polysulfate PTC299 may increase the anticoagulant activities of Pentosan Polysulfate. Approved Phenindione PTC299 may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenprocoumon PTC299 may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phenylbutazone The risk or severity of adverse effects can be increased when PTC299 is combined with Phenylbutazone. Approved, Vet Approved Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with PTC299. Approved, Investigational Pindolol PTC299 may decrease the antihypertensive activities of Pindolol. Approved, Investigational Pipemidic acid PTC299 may increase the neuroexcitatory activities of Pipemidic acid. Experimental Piretanide The therapeutic efficacy of Piretanide can be decreased when used in combination with PTC299. Approved Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with PTC299. Approved, Investigational Piromidic acid PTC299 may increase the neuroexcitatory activities of Piromidic acid. Experimental Piroxicam The risk or severity of adverse effects can be increased when PTC299 is combined with Piroxicam. Approved, Investigational Pirprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Pirprofen. Experimental Pitolisant The risk or severity of adverse effects can be increased when PTC299 is combined with Pitolisant. Approved, Investigational Platelet Activating Factor PTC299 may decrease the antihypertensive activities of Platelet Activating Factor. Experimental Plazomicin PTC299 may decrease the excretion rate of Plazomicin which could result in a higher serum level. Approved, Investigational Polythiazide The therapeutic efficacy of Polythiazide can be decreased when used in combination with PTC299. Approved Pomalidomide The risk or severity of adverse effects can be increased when PTC299 is combined with Pomalidomide. Approved Potassium Citrate PTC299 may increase the anticoagulant activities of Potassium Citrate. Approved, Investigational, Vet Approved Practolol PTC299 may decrease the antihypertensive activities of Practolol. Approved Pralatrexate The serum concentration of Pralatrexate can be increased when it is combined with PTC299. Approved, Investigational Pranoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Pranoprofen. Experimental, Investigational Prasterone The risk or severity of adverse effects can be increased when PTC299 is combined with Prasterone. Approved, Investigational, Nutraceutical Prasterone sulfate The risk or severity of adverse effects can be increased when PTC299 is combined with Prasterone sulfate. Investigational Prednicarbate The risk or severity of adverse effects can be increased when PTC299 is combined with Prednicarbate. Approved, Investigational Prednisone The risk or severity of adverse effects can be increased when PTC299 is combined with Prednisone. Approved, Vet Approved Pregnenolone The risk or severity of adverse effects can be increased when PTC299 is combined with Pregnenolone. Approved, Experimental, Investigational Probenecid The serum concentration of PTC299 can be increased when it is combined with Probenecid. Approved, Investigational Proglumetacin The risk or severity of adverse effects can be increased when PTC299 is combined with Proglumetacin. Experimental Propacetamol The risk or severity of adverse effects can be increased when PTC299 is combined with Propacetamol. Approved, Investigational Propyphenazone The risk or severity of adverse effects can be increased when PTC299 is combined with Propyphenazone. Experimental Proquazone The risk or severity of adverse effects can be increased when PTC299 is combined with Proquazone. Experimental Prostaglandin B2 The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with PTC299. Experimental Prostaglandin G2 The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with PTC299. Experimental Prostalene The therapeutic efficacy of Prostalene can be decreased when used in combination with PTC299. Vet Approved Protein C PTC299 may increase the anticoagulant activities of Protein C. Approved Protein S human PTC299 may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde PTC299 may increase the anticoagulant activities of Protocatechualdehyde. Approved Prulifloxacin PTC299 may increase the neuroexcitatory activities of Prulifloxacin. Investigational Puromycin PTC299 may decrease the excretion rate of Puromycin which could result in a higher serum level. Experimental Quinapril The risk or severity of adverse effects can be increased when PTC299 is combined with Quinapril. Approved, Investigational Quinethazone The therapeutic efficacy of Quinethazone can be decreased when used in combination with PTC299. Approved Ramipril The risk or severity of adverse effects can be increased when PTC299 is combined with Ramipril. Approved Rescinnamine The risk or severity of adverse effects can be increased when PTC299 is combined with Rescinnamine. Approved Resveratrol The risk or severity of adverse effects can be increased when PTC299 is combined with Resveratrol. Approved, Experimental, Investigational Reviparin PTC299 may increase the anticoagulant activities of Reviparin. Approved, Investigational Ribostamycin PTC299 may decrease the excretion rate of Ribostamycin which could result in a higher serum level. Approved, Investigational Rimexolone The risk or severity of adverse effects can be increased when PTC299 is combined with Rimexolone. Approved Risedronate The risk or severity of adverse effects can be increased when PTC299 is combined with Risedronate. Approved, Investigational Rivaroxaban PTC299 may increase the anticoagulant activities of Rivaroxaban. Approved Rofecoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Rofecoxib. Approved, Investigational, Withdrawn Rosoxacin PTC299 may increase the neuroexcitatory activities of Rosoxacin. Approved, Investigational Rufloxacin PTC299 may increase the neuroexcitatory activities of Rufloxacin. Experimental Sacubitril The risk or severity of adverse effects can be increased when Sacubitril is combined with PTC299. Approved Salicylamide The risk or severity of adverse effects can be increased when PTC299 is combined with Salicylamide. Approved Salsalate The risk or severity of adverse effects can be increased when PTC299 is combined with Salsalate. Approved Saprisartan The risk or severity of adverse effects can be increased when Saprisartan is combined with PTC299. Experimental Saralasin The risk or severity of adverse effects can be increased when Saralasin is combined with PTC299. Investigational Sarilumab Sarilumab may increase the immunosuppressive activities of PTC299. Approved, Investigational Seliciclib The risk or severity of adverse effects can be increased when PTC299 is combined with Seliciclib. Investigational Semapimod The risk or severity of adverse effects can be increased when PTC299 is combined with Semapimod. Investigational Seratrodast The risk or severity of adverse effects can be increased when PTC299 is combined with Seratrodast. Approved Serrapeptase The risk or severity of adverse effects can be increased when PTC299 is combined with Serrapeptase. Investigational Sisomicin PTC299 may decrease the excretion rate of Sisomicin which could result in a higher serum level. Investigational Sitafloxacin PTC299 may increase the neuroexcitatory activities of Sitafloxacin. Experimental, Investigational Sotalol PTC299 may decrease the antihypertensive activities of Sotalol. Approved Sparfloxacin PTC299 may increase the neuroexcitatory activities of Sparfloxacin. Approved, Investigational Spirapril The risk or severity of adverse effects can be increased when PTC299 is combined with Spirapril. Approved SRT501 The risk or severity of adverse effects can be increased when SRT501 is combined with PTC299. Investigational Streptomycin PTC299 may decrease the excretion rate of Streptomycin which could result in a higher serum level. Approved, Vet Approved Sulodexide PTC299 may increase the anticoagulant activities of Sulodexide. Approved, Investigational Sulprostone The therapeutic efficacy of Sulprostone can be decreased when used in combination with PTC299. Investigational Suprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Suprofen. Approved, Withdrawn Suxibuzone The risk or severity of adverse effects can be increased when PTC299 is combined with Suxibuzone. Experimental Tacrolimus PTC299 may increase the nephrotoxic activities of Tacrolimus. Approved, Investigational Tafluprost The therapeutic efficacy of Tafluprost can be decreased when used in combination with PTC299. Approved Talinolol PTC299 may decrease the antihypertensive activities of Talinolol. Investigational Talniflumate The risk or severity of adverse effects can be increased when Talniflumate is combined with PTC299. Approved Tarenflurbil The risk or severity of adverse effects can be increased when PTC299 is combined with Tarenflurbil. Investigational Tasosartan The risk or severity of adverse effects can be increased when Tasosartan is combined with PTC299. Approved Technetium Tc-99m etidronate The risk or severity of adverse effects can be increased when PTC299 is combined with Technetium Tc-99m etidronate. Approved Technetium Tc-99m medronate The risk or severity of adverse effects can be increased when PTC299 is combined with Technetium Tc-99m medronate. Approved Telmisartan The risk or severity of adverse effects can be increased when Telmisartan is combined with PTC299. Approved, Investigational Temafloxacin PTC299 may increase the neuroexcitatory activities of Temafloxacin. Withdrawn Temocapril The risk or severity of adverse effects can be increased when PTC299 is combined with Temocapril. Experimental, Investigational Tenidap The risk or severity of adverse effects can be increased when PTC299 is combined with Tenidap. Experimental Tenofovir disoproxil The risk or severity of adverse effects can be increased when PTC299 is combined with Tenofovir disoproxil. Approved, Investigational Tenoxicam The risk or severity of adverse effects can be increased when PTC299 is combined with Tenoxicam. Approved Tepoxalin The risk or severity of adverse effects can be increased when PTC299 is combined with Tepoxalin. Vet Approved Terbutaline PTC299 may decrease the antihypertensive activities of Terbutaline. Approved Teriflunomide The risk or severity of adverse effects can be increased when PTC299 is combined with Teriflunomide. Approved Tertatolol PTC299 may decrease the antihypertensive activities of Tertatolol. Experimental Tiaprofenic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Tiaprofenic acid. Approved Tiludronic acid The risk or severity of adverse effects can be increased when PTC299 is combined with Tiludronic acid. Approved, Investigational, Vet Approved Timolol PTC299 may decrease the antihypertensive activities of Timolol. Approved Tinoridine The risk or severity of adverse effects can be increased when PTC299 is combined with Tinoridine. Investigational Tixocortol The risk or severity of adverse effects can be increased when PTC299 is combined with Tixocortol. Approved, Withdrawn Tobramycin PTC299 may decrease the excretion rate of Tobramycin which could result in a higher serum level. Approved, Investigational Tolmetin The risk or severity of adverse effects can be increased when PTC299 is combined with Tolmetin. Approved Torasemide The therapeutic efficacy of Torasemide can be decreased when used in combination with PTC299. Approved Trandolapril The risk or severity of adverse effects can be increased when PTC299 is combined with Trandolapril. Approved Travoprost The therapeutic efficacy of Travoprost can be decreased when used in combination with PTC299. Approved Treprostinil The risk or severity of adverse effects can be increased when Treprostinil is combined with PTC299. Approved, Investigational Triamcinolone The risk or severity of adverse effects can be increased when PTC299 is combined with Triamcinolone. Approved, Vet Approved Triamterene PTC299 may decrease the antihypertensive activities of Triamterene. Approved Tribenoside The risk or severity of adverse effects can be increased when PTC299 is combined with Tribenoside. Experimental Trichlormethiazide The therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with PTC299. Approved, Vet Approved Triptolide The risk or severity of adverse effects can be increased when PTC299 is combined with Triptolide. Investigational Trovafloxacin PTC299 may increase the neuroexcitatory activities of Trovafloxacin. Approved, Investigational, Withdrawn Troxerutin PTC299 may increase the anticoagulant activities of Troxerutin. Investigational Ulobetasol The risk or severity of adverse effects can be increased when PTC299 is combined with Ulobetasol. Approved Unoprostone The therapeutic efficacy of Unoprostone can be decreased when used in combination with PTC299. Approved, Investigational Valdecoxib The risk or severity of adverse effects can be increased when PTC299 is combined with Valdecoxib. Approved, Investigational, Withdrawn Valsartan The risk or severity of adverse effects can be increased when Valsartan is combined with PTC299. Approved, Investigational Warfarin PTC299 may increase the anticoagulant activities of Warfarin. Approved Ximelagatran PTC299 may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Zaltoprofen The risk or severity of adverse effects can be increased when PTC299 is combined with Zaltoprofen. Approved, Investigational Zileuton The risk or severity of adverse effects can be increased when Zileuton is combined with PTC299. Approved, Investigational, Withdrawn Zofenopril The risk or severity of adverse effects can be increased when PTC299 is combined with Zofenopril. Experimental Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with PTC299. Withdrawn - Food Interactions
- Not Available
References
- General References
- Not Available
- External Links
- PubChem Substance
- 347909999
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Metastatic Breast Cancer (MBC) 1 1 Suspended Treatment Cancer, Advanced 1 2 Suspended Treatment Neurofibromatosis 2 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Taxonomy
- Classification
- Not classified
Drug created on October 21, 2007 16:24 / Updated on August 02, 2018 05:29